IBX
IMAGIONBIO FPO [IBX]
Healthcare · ASX Small Cap
$0.0220 -4.4%
Updated 2026-03-02 · Scores refresh every scan
⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Appeared in 2 consecutive scans→ Score +3First seen: 2026-02-25
Score Breakdown
Technical27
Catalyst52
Sentiment50
Fundamental6
Momentum62
Risk Gate30
Active Signals
Bullish Signals
- RSI approaching oversold
- Above-average volume (1.7x) on down day
- Critical cash runway (1.2 quarters)
- 4C filed 2026-01-28
- Moderate P/S ratio (10.7x)
- Revenue in sharp decline (-98%)
- Micro-cap ($5-20M) - high risk
- Capital raise activity (1 events)
- CANSLIM S: Tight float (36%)
- Strong 12-1 momentum (+85%)
- Altman Z-Score in distress zone (1.41 < 1.81)
- Low-priced stock risk ($0.023)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- MACD bearish crossover
- Price below MAs (downtrend)
- Negative 5-day momentum (-4.3%)
- Below 200-day MA (long-term downtrend)
- Piotroski F-Score weak (2/9)
- Deeply negative margins (-209%)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
- Revenue momentum declining (-98%)
Recent Catalysts
NONE Appendix 4G and Corporate Governance Statement
NONE Cleansing Notice
LOW FY25 Appendix 4E and Annual Report
LOW Appendix 4C and Quarterly Activities Report - December 2025
MEDIUM IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
Recent ASX Announcements
| 2026-02-27 | Appendix 4G and Corporate Governance Statement |
| 2026-02-27 | FY25 Appendix 4E and Annual Report PRICE SENSITIVE |
| 2026-02-01 | IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial PRICE SENSITIVE |
| 2026-01-28 | Appendix 4C and Quarterly Activities Report - December 2025 PRICE SENSITIVE |
| 2026-01-08 | Cleansing Notice |
Key Metrics
$11.3M
Market Cap
2.4M
Avg Volume
1.7x
Vol Ratio
$0.01 — $0.06
52-Week Range
N/A
Short Interest
1 qtrs
Cash Runway
N/A
ROE
-208.5%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 36% |
| L | Leader vs Laggard | laggard | RS: -1 |
| I | Institutional Sponsorship | weak | Inst: 0% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #117 of 119 · Sector avg: 51
View all Healthcare signals →